Comparative Pharmacology
Head-to-head clinical analysis: PYZCHIVA versus VABYSMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYZCHIVA versus VABYSMO.
PYZCHIVA vs VABYSMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biosimilar to infliximab; a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), neutralizing its activity and reducing inflammation.
Vabysmo (faricimab) is a bispecific monoclonal antibody that binds to vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), inhibiting their activity. By blocking VEGF-A, it reduces endothelial cell proliferation, vascular permeability, and angiogenesis. By inhibiting Ang-2, it stabilizes blood vessels by enhancing pericyte coverage and reducing vascular leakage and inflammation.
Intravenous infusion of 300 mg over 60 minutes on days 1, 15, and 29, then every 4 weeks thereafter.
Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL solution) once every 4 weeks (monthly) for 4 doses, then 6 mg every 8 weeks (2 months) thereafter.
None Documented
None Documented
Terminal elimination half-life approximately 21-25 days (mean 23 days), consistent with IgG1 monoclonal antibody clearance; supports monthly dosing.
Terminal elimination half-life: approximately 26 days (range 20–36 days) in clinical studies. This supports dosing every 8–16 weeks for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Primarily eliminated via the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion accounts for <5% as intact drug.
Renal elimination: Vabysmo (faricimab) is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion data are available; renal elimination of intact antibody is minimal due to high molecular weight. Biliary/fecal excretion is not a major route.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor